{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:48:50Z","timestamp":1790887730751,"version":"4.1.0"},"reference-count":186,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.bbcan.2024.189240","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T16:31:27Z","timestamp":1734021087000},"page":"189240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Kidney cancer: From tumor biology to innovative therapeutics"],"prefix":"10.1016","volume":"1880","author":[{"given":"Laura","family":"Rinaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Senatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Feliciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Chiuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Insabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Feliciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2024.189240_bb0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International variations and trends in renal cell carcinoma incidence and mortality","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","article-title":"Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review","volume":"34","author":"Gupta","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2024.189240_bb0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41585-019-0211-5","article-title":"The Cancer genome atlas of renal cell carcinoma: findings and clinical implications","volume":"16","author":"Linehan","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0020","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.ackd.2013.10.001","article-title":"Hereditary kidney cancer syndromes","volume":"21","author":"Haas","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"10.1016\/j.bbcan.2024.189240_bb0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-019-0780-z","article-title":"Emerging therapeutic agents for genitourinary cancers","volume":"12","author":"Zarrabi","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0040","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ucl.2008.07.005","article-title":"Epidemiology, clinical staging, and presentation of renal cell carcinoma","volume":"35","author":"Decastro","year":"2008","journal-title":"Urol. Clin. North Am."},{"key":"10.1016\/j.bbcan.2024.189240_bb0045","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/ijerph15061089","article-title":"Racial disparities and preventive measures to renal cell carcinoma","volume":"15","author":"Sims","year":"2018","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.bbcan.2024.189240_bb0050","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1200\/JCO.2010.30.9484","article-title":"Cigarette smoking is associated with advanced renal cell carcinoma","volume":"29","author":"Tsivian","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0055","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/EDE.0b013e3182300720","article-title":"Hypertension and risk of renal cell carcinoma among white and black Americans","volume":"22","author":"Colt","year":"2011","journal-title":"Epidemiology"},{"key":"10.1016\/j.bbcan.2024.189240_bb0060","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1002\/ijc.21765","article-title":"Fruits and vegetables and renal cell carcinoma: findings from the European prospective investigation into cancer and nutrition (EPIC)","volume":"118","author":"Weikert","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2024.189240_bb0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2024.189240_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An immune atlas of clear cell renal cell carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0075","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.cell.2019.10.007","article-title":"Integrated Proteogenomic characterization of clear cell renal cell carcinoma","volume":"179","author":"Clark","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0085","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1038\/s41467-024-49692-1","article-title":"Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma","volume":"15","author":"Culliford","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2024.189240_bb0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15586\/jkcvhl.v10i4.294","article-title":"Papillary renal cell carcinoma: demographics, survival analysis, racial disparities, and genomic landscape","volume":"10","author":"Ullah","year":"2023","journal-title":"J. Kidney Cancer VHL"},{"key":"10.1016\/j.bbcan.2024.189240_bb0095","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-020-0301-x","article-title":"Genomic profiling in renal cell carcinoma","volume":"16","author":"Dizman","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0100","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ccell.2023.07.006","article-title":"Chromophobe renal cell carcinoma","volume":"41","author":"Henske","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0105","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-20-1998","article-title":"Endocytosis-mediated replenishment of amino acids favors Cancer cell proliferation and survival in chromophobe renal cell carcinoma","volume":"80","author":"Xiao","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189240_bb0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00000478-200404000-00002","article-title":"Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome","volume":"28","author":"Cheville","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0115","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41379-019-0269-x","article-title":"JAK2\/PD-L1\/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management","volume":"32","author":"Gupta","year":"2019","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0120","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00428-024-03872-y","article-title":"PAX8 expression in cancerous and non-neoplastic tissue: a tissue microarray study on more than 17,000 tumors from 149 different tumor entities","volume":"485","author":"Gorbokon","year":"2024","journal-title":"Virchows Arch."},{"key":"10.1016\/j.bbcan.2024.189240_bb0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.eururo.2023.04.030","article-title":"Re: WHO classification of Tumours, 5th edition, volume 8: urinary and male genital Tumours","volume":"84","author":"Tateo","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0130","article-title":"What\u2019s new in the WHO 2022 classification of kidney tumours?","volume":"1\u201315","author":"Alaghehbandan","year":"2023","journal-title":"Pathologica"},{"key":"10.1016\/j.bbcan.2024.189240_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102882","article-title":"New rising entities in cancer of unknown primary: is there a real therapeutic benefit?","volume":"147","author":"Rassy","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0140","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(04)15957-6","article-title":"Hippel-Lindau disease","volume":"363","author":"Richard","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2024.189240_bb0145","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.febslet.2012.04.032","article-title":"Systemic VHL gene functions and the VHL disease","volume":"586","author":"Bader","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbcan.2024.189240_bb0150","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2024.189240_bb0155","doi-asserted-by":"crossref","first-page":"44966","DOI":"10.1074\/jbc.M305502200","article-title":"Hypoxia inducible factor activates the transforming growth factor-alpha\/epidermal growth factor receptor growth stimulatory pathway in VHL(\u2212\/\u2212) renal cell carcinoma cells","volume":"278","author":"Gunaratnam","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2024.189240_bb0160","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1128\/MCB.00892-06","article-title":"VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail","volume":"27","author":"Evans","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0165","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.onc.1208305","article-title":"Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma","volume":"24","author":"Petrella","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2024.189240_bb0170","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature09141","article-title":"HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase","volume":"465","author":"Sendoel","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2024.189240_bb0175","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2024.189240_bb0180","first-page":"245","article-title":"Coexpression of transforming growth factor-alpha and \u00e9pidermal growth factor receptor in capillary hemangioblastomas of the central nervous system","volume":"147","author":"Reifenberger","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0304-3835(95)03915-J","article-title":"Selective tumorigenesis in non-parenchymal liver epithelial cell lines by hepatocyte growth factor transfection","volume":"96","author":"Johnson","year":"1995","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2024.189240_bb0190","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","article-title":"Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer","volume":"19","author":"Linehan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189240_bb0195","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.juro.2012.08.030","article-title":"Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer","volume":"188","author":"Ricketts","year":"2012","journal-title":"J. Urol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semcdb.2019.04.013","article-title":"Regulation of succinate dehydrogenase and role of succinate in cancer","volume":"98","author":"Dalla Pozza","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047842","article-title":"Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion","volume":"7","author":"Medvetz","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2024.189240_bb0210","article-title":"Neural processing without O2 and glucose delivery: lessons from the pond to the clinic","volume":"39","author":"Amaral-Silva","year":"2024","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.bbcan.2024.189240_bb0215","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0220","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1159\/000320891","article-title":"Tuberous sclerosis complex renal disease","volume":"118","author":"Dixon","year":"2011","journal-title":"Nephron Exp. Nephrol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0225","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41581-023-00800-2","article-title":"Metabolic alterations in hereditary and sporadic renal cell carcinoma","volume":"20","author":"Coffey","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0230","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13000-023-01341-9","article-title":"Eosinophilic solid and cystic renal cell carcinoma with TSC2 mutation: a case report and literature review","volume":"18","author":"He","year":"2023","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0235","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41379-021-00737-6","article-title":"Novel, emerging and provisional renal entities: the genitourinary pathology society (GUPS) update on renal neoplasia","volume":"34","author":"Trpkov","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0240","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2024.189240_bb0245","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1073\/pnas.94.6.2156","article-title":"The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins","volume":"94","author":"Pause","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2024.189240_bb0250","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2024.189240_bb0255","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.biochi.2008.10.019","article-title":"Polybromo-1: the chromatin targeting subunit of the PBAF complex","volume":"91","author":"Thompson","year":"2009","journal-title":"Biochimie"},{"key":"10.1016\/j.bbcan.2024.189240_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153718","article-title":"PBRM1 regulates the expression of genes involved in metabolism and cell adhesion in renal clear cell carcinoma","volume":"11","author":"Chowdhury","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2024.189240_bb0265","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1073\/pnas.091533398","article-title":"The HMG-domain protein BAP111 is important for the function of the BRM chromatin-remodeling complex in vivo","volume":"98","author":"Papoulas","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2024.189240_bb0270","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.ajhg.2021.07.009","article-title":"Altered regulation of DPF3, a member of the SWI\/SNF complexes, underlies the 14q24 renal cancer susceptibility locus","volume":"108","author":"Colli","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbcan.2024.189240_bb0275","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1038\/s41467-022-32472-0","article-title":"The SWI\/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-\u03b2 signaling","volume":"13","author":"Cui","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2024.189240_bb0280","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/0008-5472.CAN-08-3355","article-title":"BRCA1-associated protein 1 interferes with BRCA1\/BARD1 RING heterodimer activity","volume":"69","author":"Nishikawa","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189240_bb0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3233\/KCA-210006","article-title":"BRCA1-associated protein 1 (BAP-1) as a prognostic and predictive biomarker in clear cell renal cell carcinoma: a systematic review","volume":"6","author":"Gulati","year":"2022","journal-title":"KCA"},{"key":"10.1016\/j.bbcan.2024.189240_bb0290","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2024.189240_bb0300","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3390\/biomedicines9121896","article-title":"Lactotransferrin downregulation serves as a potential predictor for the therapeutic effectiveness of mTOR inhibitors in the metastatic clear cell renal cell carcinoma without PTEN mutation","volume":"9","author":"Zheng","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbcan.2024.189240_bb0305","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy","volume":"18","author":"Comoglio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2024.189240_bb0310","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nm.3441","article-title":"Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure","volume":"20","author":"Ablain","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0315","doi-asserted-by":"crossref","DOI":"10.1038\/s44321-024-00077-3","article-title":"PML restrains p53 activity and cellular senescence in clear cell renal cell carcinoma","author":"Simoni","year":"2024","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0320","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1038\/s41467-019-13608-1","article-title":"PBRM1 acts as a p53 lysine-acetylation reader to suppress renal tumor growth","volume":"10","author":"Cai","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2024.189240_bb0325","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02482","article-title":"SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint","volume":"3","author":"Carvalho","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.bbcan.2024.189240_bb0330","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jss.2019.10.044","article-title":"Global disparities in wilms tumor","volume":"247","author":"Cunningham","year":"2020","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.bbcan.2024.189240_bb0335","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(90)90601-A","article-title":"Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms\u2019 tumor locus","volume":"60","author":"Call","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0340","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2024.189240_bb0345","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1016\/j.clgc.2018.02.013","article-title":"Clinical relevance of gene copy number variation in metastatic clear cell renal cell carcinoma","volume":"16","author":"Nouhaud","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bbcan.2024.189240_bb0350","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0355","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41418-022-00941-0","article-title":"The multifaceted role of ferroptosis in liver disease","volume":"29","author":"Chen","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2024.189240_bb0360","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41419-023-06144-w","article-title":"Emerging significance and therapeutic targets of ferroptosis: a potential avenue for human kidney diseases","volume":"14","author":"Li","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2024.189240_bb0365","doi-asserted-by":"crossref","first-page":"28351","DOI":"10.18632\/oncotarget.25322","article-title":"Increased Nrf2 expression by renal cell carcinoma is associated with postoperative chronic kidney disease and an unfavorable prognosis","volume":"9","author":"Yuki","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2024.189240_bb0370","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/s41467-019-09277-9","article-title":"A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis","volume":"10","author":"Zou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2024.189240_bb0375","doi-asserted-by":"crossref","first-page":"E6274","DOI":"10.1073\/pnas.1710849115","article-title":"Impairment of gamma-glutamyl transferase 1 activity in the metabolic pathogenesis of chromophobe renal cell carcinoma","volume":"115","author":"Priolo","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2024.189240_bb0380","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1158\/0008-5472.CAN-20-0754","article-title":"Decreased mitochondrial DNA content drives OXPHOS dysregulation in Chromophobe renal cell carcinoma","volume":"80","author":"Xiao","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189240_bb0385","article-title":"Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11","volume":"119","author":"Zhang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2024.189240_bb0390","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121987119","article-title":"A ferroptosis defense mechanism mediated by glycerol-3-phosphate dehydrogenase 2 in mitochondria","volume":"119","author":"Wu","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbcan.2024.189240_bb0395","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.bbcan.2024.189240_bb0400","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.4155\/fmc.15.148","article-title":"Targeting ubiquitination for cancer therapies","volume":"7","author":"Morrow","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bbcan.2024.189240_bb0405","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/cells12020234","article-title":"Control of mitochondrial activity by the ubiquitin code in health and Cancer","volume":"12","author":"Rinaldi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2024.189240_bb0410","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12882-023-03215-0","article-title":"A risk signature of ubiquitin-specific protease family predict the prognosis and therapy of kidney cancer patients","volume":"24","author":"Wang","year":"2023","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1158\/1078-0432.CCR-06-0824","article-title":"Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration","volume":"13","author":"Seliger","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189240_bb0420","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.humpath.2022.07.022","article-title":"The expanding role of BAP1 in clear cell renal cell carcinoma","volume":"133","author":"Kapur","year":"2023","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0425","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s42003-024-05823-4","article-title":"Downregulation of praja2 restrains endocytosis and boosts tyrosine kinase receptors in kidney cancer","volume":"7","author":"Rinaldi","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.bbcan.2024.189240_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104621","article-title":"TRIM28 represses renal cell carcinoma cell proliferation by inhibiting TFE3\/KDM6A-regulated autophagy","volume":"299","author":"Song","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2024.189240_bb0435","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.833086","article-title":"Pathophysiology of primary cilia: signaling and Proteostasis regulation","volume":"10","author":"Senatore","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0440","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.cell.2009.03.023","article-title":"The vertebrate primary cilium in development, homeostasis, and disease","volume":"137","author":"Gerdes","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0445","series-title":"Methods in Cell Biology","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0091-679X(08)94007-3","article-title":"Primary cilia and the cell cycle","volume":"vol. 94","author":"Plotnikova","year":"2009"},{"key":"10.1016\/j.bbcan.2024.189240_bb0450","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fcell.2018.00008","article-title":"Signaling through the primary cilium","volume":"6","author":"Wheway","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0455","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0070-2153(08)00807-7","article-title":"Ciliary function and Wnt signal modulation","volume":"85","author":"Gerdes","year":"2008","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0460","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.952055","article-title":"Primary cilium in kidney development, function and disease","volume":"13","author":"Bai","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.bbcan.2024.189240_bb0465","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2046-2530-3-7","article-title":"Loss of primary cilia occurs early in breast cancer development","volume":"3","author":"Menzl","year":"2014","journal-title":"Cilia"},{"key":"10.1016\/j.bbcan.2024.189240_bb0470","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2046-2530-1-15","article-title":"Primary cilia and aberrant cell signaling in epithelial ovarian cancer","volume":"1","author":"Egeberg","year":"2012","journal-title":"Cilia"},{"key":"10.1016\/j.bbcan.2024.189240_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068521","article-title":"Primary cilia are lost in preinvasive and invasive prostate cancer","volume":"8","author":"Hassounah","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2024.189240_bb0480","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.4343","article-title":"Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice","volume":"23","author":"Harlander","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0485","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/modpathol.2008.132","article-title":"Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia","volume":"22","author":"Schraml","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0490","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2046-2530-2-2","article-title":"Reduced cilia frequencies in human renal cell carcinomas versus neighboring parenchymal tissue","volume":"2","author":"Basten","year":"2013","journal-title":"Cilia"},{"key":"10.1016\/j.bbcan.2024.189240_bb0495","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1681\/ASN.2006020181","article-title":"Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein","volume":"17","author":"Esteban","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0500","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1074\/jbc.M114.589226","article-title":"The tumor suppressor pVHL Down-regulates never-in-mitosis A-related kinase 8 via hypoxia-inducible factors to maintain cilia in human renal cancer cells","volume":"290","author":"Ding","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2024.189240_bb0505","article-title":"Therapeutically actionable signaling node to rescue AURKA driven loss of primary cilia in VHL-deficient cells","volume":"11","author":"Chowdhury","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2024.189240_bb0510","article-title":"STIL acts as an oncogenetic driver in a primary cilia-dependent manner in human cancer","volume":"10","author":"Li","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0515","doi-asserted-by":"crossref","first-page":"F905","DOI":"10.1152\/ajprenal.00427.2011","article-title":"Carcinogens induce loss of the primary cilium in human renal proximal tubular epithelial cells independently of effects on the cell cycle","volume":"302","author":"Radford","year":"2012","journal-title":"Am. J, Physiol.-Renal Physiol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0520","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neo.2020.12.002","article-title":"DAB2IP modulates primary cilia formation associated with renal tumorigenesis","volume":"23","author":"Lin","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbcan.2024.189240_bb0525","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bbrc.2018.01.079","article-title":"Deficiency of primary cilia in kidney epithelial cells induces epithelial to mesenchymal transition","volume":"496","author":"Han","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2024.189240_bb0530","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.18632\/oncotarget.7198","article-title":"Identification of drugs that restore primary cilium expression in cancer cells","volume":"7","author":"Khan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2024.189240_bb0535","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbcan.2024.189240_bb0540","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2024.189240_bb0545","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/jcp.30130","article-title":"Overexpression of enolase 2 is associated with worsened prognosis and increased glycikolysis in papillary renal cell carcinoma","volume":"236","author":"Sun","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0550","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41467-021-27660-3","article-title":"Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2024.189240_bb0555","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s00432-020-03278-8","article-title":"Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors","volume":"146","author":"Simon","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0560","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/0008-5472.CAN-14-1703","article-title":"Grade-dependent metabolic reprogramming in kidney Cancer revealed by combined proteomics and metabolomics analysis","volume":"75","author":"Wettersten","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189240_bb0565","doi-asserted-by":"crossref","first-page":"9012","DOI":"10.1111\/jcmm.15536","article-title":"Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma","volume":"24","author":"Xu","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0570","article-title":"Mitochondrial metabolism in primary and metastatic human kidney cancers","author":"Bezwada","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.bbcan.2024.189240_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103857","article-title":"Epigenetics in advanced renal cell carcinoma: potential new targets","volume":"180","author":"Molina-Cerrillo","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0580","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0585","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41580-018-0059-1","article-title":"Regulation of microRNA biogenesis and its crosstalk with other cellular pathways","volume":"20","author":"Treiber","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0590","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2024.189240_bb0595","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77774-9","article-title":"Detection of urinary miRNAs for diagnosis of clear cell renal cell carcinoma","volume":"10","author":"Cochetti","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2024.189240_bb0600","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/clinchem\/hvad133","article-title":"Diagnostic miRNA signatures in paired tumor, plasma, and urine specimens from renal cell carcinoma patients","volume":"70","author":"Bustos","year":"2024","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbcan.2024.189240_bb0605","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1038\/s41598-024-59337-4","article-title":"Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma","volume":"14","author":"Soleimani","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2024.189240_bb0610","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00432-009-0726-x","article-title":"Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues","volume":"136","author":"Yi","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0615","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.juro.2011.04.110","article-title":"miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation","volume":"186","author":"White","year":"2011","journal-title":"J. Urol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0620","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12943-023-01912-w","article-title":"CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p\/CYP1B1 axis","volume":"23","author":"Zheng","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2024.189240_bb0625","doi-asserted-by":"crossref","first-page":"20324","DOI":"10.18632\/oncotarget.7951","article-title":"miR-155 regulates the proliferation and invasion of clear cell renal cell carcinoma cells by targeting E2F2","volume":"7","author":"Gao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2024.189240_bb0630","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/path.2860","article-title":"Overexpression of miR-210, a downstream target of HIF1\u03b1, causes centrosome amplification in renal carcinoma cells","volume":"224","author":"Nakada","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0635","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4161\/cc.8.17.9387","article-title":"MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT","volume":"8","author":"Zhang","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2024.189240_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155254","article-title":"miRNAs role in Wilms tumor pathogenesis: signaling pathways interplay","volume":"256","author":"Alfaifi","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbcan.2024.189240_bb0645","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1126\/science.2011739","article-title":"Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR","volume":"251","author":"Gatignol","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2024.189240_bb0650","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138920210793175895","article-title":"MicroRNA: biogenesis, function and role in cancer","volume":"11","author":"Macfarlane","year":"2010","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.bbcan.2024.189240_bb0655","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","article-title":"Histone post-translational modifications - cause and consequence of genome function","volume":"23","author":"Mill\u00e1n-Zambrano","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbcan.2024.189240_bb0660","doi-asserted-by":"crossref","first-page":"8189","DOI":"10.1038\/s41598-019-44733-y","article-title":"Reduction in H3K4me patterns due to aberrant expression of methyltransferases and demethylases in renal cell carcinoma: prognostic and therapeutic implications","volume":"9","author":"Kumar","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2024.189240_bb0665","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/PPO.0b013e3182a09e07","article-title":"Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma","volume":"19","author":"Ramakrishnan","year":"2013","journal-title":"Cancer J."},{"key":"10.1016\/j.bbcan.2024.189240_bb0670","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41467-023-35833-5","article-title":"Epigenomic charting and functional annotation of risk loci in renal cell carcinoma","volume":"14","author":"Nassar","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2024.189240_bb0675","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s43018-021-00316-3","article-title":"SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes","volume":"3","author":"Xie","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2024.189240_bb0680","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12094-014-1195-5","article-title":"EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma","volume":"17","author":"Xu","year":"2015","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0685","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/bju.12702","article-title":"Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma","volume":"117","author":"Liu","year":"2016","journal-title":"BJU Int."},{"key":"10.1016\/j.bbcan.2024.189240_bb0690","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3892\/ijo.2024.5633","article-title":"Lysine methyltransferase 5C increases the proliferation and metastatic abilities of clear cell renal cell carcinoma via aerobic glycolysis","volume":"64","author":"Zeng","year":"2024","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0695","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1135404","article-title":"Epigenetics and immune cells in medulloblastoma","volume":"14","author":"Gorini","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbcan.2024.189240_bb0700","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1038\/sj.onc.1205600","article-title":"CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future","volume":"21","author":"Esteller","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2024.189240_bb0705","first-page":"58","article-title":"Genetic and epigenetic alterations during renal carcinogenesis","volume":"4","author":"Arai","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0710","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.gdata.2016.10.008","article-title":"Analysis of distribution of DNA methylation in kidney-renal-clear-cell-carcinoma specific genes using entropy","volume":"10","author":"Ramakrishnan","year":"2016","journal-title":"Genom. Data"},{"key":"10.1016\/j.bbcan.2024.189240_bb0715","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/ijms19092529","article-title":"Clinicopathologic significance of VHL gene alteration in clear-cell renal cell carcinoma: an updated Meta-analysis and review","volume":"19","author":"Kim","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2024.189240_bb0720","doi-asserted-by":"crossref","first-page":"11149","DOI":"10.1002\/cam4.5698","article-title":"Role of tumor microenvironment in cancer progression and therapeutic strategy","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0725","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/cancers12113393","article-title":"Altered tissue and plasma levels of fibroblast activation protein-\u03b1 (FAP) in renal Tumours","volume":"12","author":"Solano-Iturri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2024.189240_bb0730","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"van Niel","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0735","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41571-018-0036-9","article-title":"Extracellular vesicles in cancer - implications for future improvements in cancer care","volume":"15","author":"Xu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0740","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1263834","article-title":"Application of cell-derived exosomes in the hematological malignancies therapy","volume":"14","author":"Ghaffari","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814356","article-title":"Exosomes in the diagnosis and treatment of renal cell cancer","volume":"24","author":"Boussios","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2024.189240_bb0750","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000520304","article-title":"Exosomes derived from cancer-associated fibroblasts regulate cell progression in clear-cell renal-cell carcinoma","volume":"146","author":"Fu","year":"2022","journal-title":"Nephron"},{"key":"10.1016\/j.bbcan.2024.189240_bb0755","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1126\/science.aat1699","article-title":"Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors","volume":"361","author":"Young","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2024.189240_bb0760","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc0170","article-title":"ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma","volume":"13","author":"Khanna","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0765","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","article-title":"Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications","volume":"14","author":"Fang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2024.189240_bb0770","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.3390\/ijms22073765","article-title":"Anti-Angiogenic therapy: current challenges and future perspectives","volume":"22","author":"Lopes-Coelho","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2024.189240_bb0775","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2017.04.010","article-title":"Progress in tumor-associated macrophage (TAM)-targeted therapeutics","volume":"114","author":"Ngambenjawong","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2024.189240_bb0780","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1166487","article-title":"Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy","volume":"14","author":"Khan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0785","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00262-013-1487-6","article-title":"Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma","volume":"62","author":"Santoni","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2024.189240_bb0790","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1349-7006.2011.01945.x","article-title":"Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma","volume":"102","author":"Komohara","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2024.189240_bb0795","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.985082","article-title":"Immune signature of tumor infiltrating immune cells in renal cancer","volume":"4","author":"Geissler","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2024.189240_bb0800","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0805","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ccell.2021.02.013","article-title":"Progressive immune dysfunction with advancing disease stage in renal cell carcinoma","volume":"39","author":"Braun","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2024.189240_bb0810","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2005.07.008","article-title":"Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention","volume":"16","author":"Whiteside","year":"2006","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107181","article-title":"Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas","volume":"203","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2024.189240_bb0820","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0825","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/d41573-023-00186-7","article-title":"The renal cell carcinoma drug market","volume":"17","author":"Tur","year":"2024","journal-title":"Nature rReviewes Drug Discovery"},{"key":"10.1016\/j.bbcan.2024.189240_bb0830","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"R.C.Kane","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189240_bb0835","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1592\/phco.27.8.1125","article-title":"Sorafenib and sunitinib: novel targeted therapies for renal cell cancer","volume":"27","author":"Grandinetti","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbcan.2024.189240_bb0840","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0845","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0850","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0855","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bib928","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s11912-024-01613-7","article-title":"Tivozanib monotherapy in the frontline setting for patients with metastatic renal cell carcinoma and favorable prognosis","volume":"26","author":"Frazer","year":"2024","journal-title":"Current Oncology reports"},{"key":"10.1016\/j.bbcan.2024.189240_bb0860","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0865","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2024.189240_bb0870","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"24","author":"Brown","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0875","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12935-022-02816-3","article-title":"Clinical potential of PD-1\/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy","volume":"22","author":"M.Jahangir","year":"2022","journal-title":"Cancer Cell iInt"},{"key":"10.1016\/j.bbcan.2024.189240_bb0880","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0885","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0890","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0895","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0900","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2024.189240_bb0905","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2024.189240_bb0910","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus Everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2024.189240_bb0915","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clgc.2015.07.010","article-title":"Bevacizumab monotherapy as salvage therapy for advanced clear cell renal cell carcinoma pretreated with targeted drugs","volume":"14","author":"Lee","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.bbcan.2024.189240_bb0025","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2024.189240_bb0030","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41568-024-00723-5","article-title":"Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance","volume":"24","author":"Wellhausen","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2024.189240_bb0920","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-024-01061-1","article-title":"CD28 co-stimulation: novel insights and applications in cancer immunotherapy","author":"Lotze","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2024.189240_bb0925","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24001719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24001719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T23:15:48Z","timestamp":1737587748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X24001719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":186,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0304419X24001719"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189240","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney cancer: From tumor biology to innovative therapeutics","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189240"}}